Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Recruiting now · Phase 1/Phase 2
Conditions studied: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
In brief
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).
Key facts
- Study ID
- NCT05482893
- Run by
- Phanes Therapeutics
- People needed
- 258
- Starts
- 2023-03-15
- Expected to finish
- 2028-04-01
- Last updated by the study team
- 2026-07-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California, United States (enrolling)
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- Sarah Cannon Research Institute (SCRI) — Denver, Colorado, United States (enrolling)
- University of Iowa — Iowa City, Iowa, United States (enrolling)
- Norton Cancer Institute — Louisville, Kentucky, United States (enrolling)
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin, United States (enrolling)
- Duke Cancer Center — Durham, North Carolina, United States (enrolling)
- University of Pittsburgh Medical Center (UPMC) — Pittsburgh, Pennsylvania, United States (enrolling)
- MD Anderson Cancer Center, GI Medical Oncology Dept — Houston, Texas, United States (enrolling)
- NEXT Oncology — Fairfax, Virginia, United States (enrolling)
- Dana-Farber Cancer Institute (DFCI) — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.